GREY:ICOTF - Post by User
Post by
Alphastoxon Jan 03, 2013 9:41am
248 Views
Post# 20791888
iCo Announces Positive ICO-007 Phase 2 Clinical Up
iCo Announces Positive ICO-007 Phase 2 Clinical Up Highlights:
ICO has just announced its interim Phase II Update. The update is positive and we are pleased with the progress. The number of patients enrolled exceeded our expectation by nearly 50%.
Key Points:
-Recruitment has reached (and surpassed) the threshold for clinical significance. This means that the company doesn't need to recruit 204 patients (as previously discussed) 204 patients was the maximum number of patients needed). With 149 patients there is not a need for further recruitment as decided upon by the clinicians. This should further reduce the cost of the trial by $1.6MM.
-149 patients at multiple months and not a single SAE or drop out. This is of significance to potential pharma partners that are more concerned w/ safety during licensing negotiations...there have been a number of licensing and M&A transactions that have ended up as a bust due to a safety issue, so the industry is very careful re. safety before cutting cheques
-Another trial update will be provided in the next 3-4 months
Alphastox will keep you updated. To View the Full Release: https://alphastox.com/ico-therapeutics-announces-positive-ico-007-phase-2-clinical-update/